01:46 , Feb 8, 2019 |  BC Week In Review  |  Company News

I-Mab, Bio-Cancer partner to advance biotherapeies

I-Mab Biopharma (Shanghai, China) and Bio-Cancer Treatment International Ltd. (Hong Kong, China) partnered to establish a translational medicine lab in Hong Kong and implement an arginine depletion therapy and biomarker study. The translational lab will...
20:49 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Neuroendocrine tumors Cell culture and mouse studies suggest inhibiting arginine-mediated signaling of the ARG2-SLC7A1 axis could help treat neuroblastoma. In a human neuroblastoma cell line, an shRNA against ARG2 decreased proliferation compared with a...
07:00 , Apr 28, 2014 |  BioCentury  |  Emerging Company Profile

Aeglea: Old enzymes, new tricks

Aeglea BioTherapeutics Holdings LLC is developing enzymes to starve tumors that depend on outside sources of specific amino acids. Aeglea's engineered human enzymes may offer lower immunogenicity and greater activity than natural versions further along...